Mosapride

ALIMENTARY TRACT AND METABOLISM

Key facts

Mosapride is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1998. DrugCentral lists 15 molecular targets, including HTR4, HTR4 and SIGMAR1.

• Molecular targets: HTR4, HTR4, SIGMAR1 and HTR2B (15 listed in DrugCentral).
• ATC code: A03FA09 (Propulsives).
• Molecular formula: C21H25ClFN3O3; molecular weight 421.90 g/mol.

Mechanism & targets

Molecular targets (15)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 4	HTR4	unknown	Ki 7.16
5-hydroxytryptamine receptor 4	HTR4	agonist	Ki 6.90
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 6.89
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 6.72
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 6.68
Cytochrome P450 1A2	CYP1A2	unknown	IC50 6.40
Cytochrome P450 3A4	CYP3A4	unknown	IC50 6.16
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.06
Cytochrome P450 2C19	CYP2C19	unknown	IC50 6.00
Cytochrome P450 2C9	CYP2C9	unknown	IC50 6.00
Serotonin 3 (5-HT3) receptor	Htr3a|Htr3b	unknown	Ki 5.92
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 5.86
5-hydroxytryptamine receptor 3A	HTR3A	unknown	Ki 5.70
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 5.69
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 5.32

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1998-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
A03FA09	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › PROPULSIVES › Propulsives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hepatic function abnormal	206.4
Interstitial lung disease	134.2
Pneumonia aspiration	119.1
Platelet count decreased	116.9
Decreased appetite	89.6
Cerebral infarction	89.1
Renal impairment	75.7
Ileus	74.4
Altered state of consciousness	71.6
Neutrophil count decreased	66.3
Aspartate aminotransferase increased	66.0
Drug ineffective	64.1

Chemical structure

• Molecular formula: C₂₁H₂₅ClFN₃O₃
• Molecular weight: 421.90 g/mol
• CAS number: 112885-41-3
• InChIKey: YPELFRMCRYSPKZ-UHFFFAOYSA-N
• PubChem CID: 119584

CCOC1=C(C=C(Cl)C(N)=C1)C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Mosapride work?

Its molecular targets in DrugCentral include HTR4, HTR4 (agonist), SIGMAR1 and HTR2B.

When was Mosapride first approved?

Mosapride was first approved by the YEAR INTRODUCED in 1998.

What is the chemical formula of Mosapride?

Mosapride has the molecular formula C21H25ClFN3O3 and a molecular weight of 421.90 g/mol.

Sources

• DrugCentral drug card 1848 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1733174 — compound record and bioactivity
• PubChem CID 119584 — chemical identifiers
• DrugBank DB11675 — drug record
• FDA UNII I8MFJ1C0BY — substance identity
• UniProt Q13639 (HTR4) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• UniProt P41595 (HTR2B) — target protein
• UniProt P28335 (HTR2C) — target protein
• UniProt P05177 (CYP1A2) — target protein
• UniProt P08684 (CYP3A4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.